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Introduction
Brain metastases are the most common malignancy encountered 
in the central nervous system (CNS). Conventional therapeutic 
options have included resection, whole brain radiotherapy 
(WBRT), and stereotactic radiosurgery (SRS), with a very limited 
historical role for chemotherapy. However, targeted agents with 
blood-brain barrier (BBB)-penetrating capabilities, as well as 
immune checkpoint inhibitors (ICI) are expanding the role of 
systemic therapies in select subsets of patients, and current 
research focuses on identifying the best combinatorial approaches. 
WBRT has served as a component of treatment for several 
decades, but its role is rapidly evolving. It has proven ben-
eficial in symptomatic patients for palliative relief, as primary 
treatment for brain metastases in patients who are expected to 
experience longer-term survival and in whom other treatments are 
not possible, as adjuvant therapy to lower recurrence rates after 
either resection or SRS, and as prophylactic treatment for 
systemic cancers that have a greater likelihood of intrac-
ranial spread. The cognitive toxicity of WBRT, however, 
cannot be ignored as the long-term sequelae can significantly 
impact quality of life; approaches that minimize this will be 
reviewed. SRS has been ascendant because of a lower cognitive 
dysfunction profile, and we shall review current clinical trials 
redefining the roles of these therapies. With the advent of targeted 
and immunological agents, the therapeutic landscape is shifting 
once again, and, as we shall demonstrate, novel molecular insights 
will most likely set the stage for revolutionary future advances.
Overview of recent randomized radiotherapy clinical 
trials
Although WBRT is one of the standard treatment options for 
patients with brain metastasis, until recently, only one trial had 
compared the efficacy of WBRT vs. medical management. In 
1971, the Eastern Cooperative Oncology Group (ECOG) reported 
on a study of 48 patients with brain metastases randomized to 
prednisone with or without WBRT1. Clinical criteria were used 
to assess improvement in the patients’ status. WBRT prolonged 
both the duration of clinical remission (11 vs. 5 weeks, statisti-
cally significant, a relative improvement of 120%) and overall 
survival (median 14 vs. 10 weeks, relative improvement of 
40%, but P = ns, underpowered to detect a survival benefit).
The value of WBRT was re-examined in the Medical Research 
Council (MRC) QUARTZ trial. In this study, 538 patients with 
non-small cell lung cancer (NSCLC) with brain metastasis unsuit-
able for surgery or SRS and in whom there was “uncertainty in 
the clinicians’ or patients’ minds about the potential benefit of 
WBRT” were randomized to dexamethasone and WBRT (20 
Gy/5 fractions) versus dexamethasone and supportive care alone2. 
This trial reported no difference in quality adjusted life days 
(46.4 with WBRT vs. 41.7 with supportive care; the measure 
of quality included dexamethasone-induced issues, and dex-
amethasone was used in both arms) - the primary endpoint of 
the study - and only a five day difference in median survival2. 
What should practitioners take away from this trial? Quite 
simply, in patients with brain metastasis with a very short 
expected survival (similar to the poor outcomes observed in 
patients treated before the 1970s), hospice care and supportive 
management alone is appropriate.
The role of radiation therapy after surgery for patients with brain 
metastasis has been evaluated in randomized trials. The Patch-
ell study, published 20 years ago, demonstrated that, in patients 
with a single brain metastasis, WBRT after surgery reduced the 
rate of surgical bed and distant brain relapse, and neurologic 
death3. In the more recent MD Anderson Cancer Center (MDACC) 
study, patients who underwent resection of brain metastasis 
were randomized to observation or SRS. SRS improved the 
12-month rate of local control (72% vs. 45%) and median time 
to local recurrence (not reached vs. 7.6 months) but SRS nei-
ther reduced the rate of distant brain failure nor did it improve 
overall survival4. One important finding was the poor local 
control (<50% at 12-months) observed in lesions >2.5 cm, 
underscoring the need to improve outcomes through improved 
resection cavity delineation, dose-escalation, fractionated radio-
surgery, or use of pre-op SRS5. Although this trial supports the 
use of SRS after surgery, physicians need to caution patients 
about the significant risks of distant brain and/or leptomeningeal 
failure in the setting of focal therapy alone6.
In the EORTC trial, after local therapy (SRS or surgery) patients 
were randomized to observation or WBRT. WBRT significantly 
reduced intracranial relapse (both local and distant) as well 
as neurologic death, but without prolonging overall survival7. 
To explore SRS as an alternative to WBRT, the N107C trial 
compared these two modalities. Patients undergoing resection 
of a brain metastasis were randomized to WBRT or SRS to the 
resection cavity with SRS allowed to other intact metastases. The 
primary endpoint, cognitive deterioration-free survival, was 
judged to be a single standard deviation reduction in any sin-
gle cognitive domain. Although there was a two week benefit in 
cognitive preservation in the SRS arm compared to the WBRT 
arm (approximately the time needed to deliver WBRT), more 
striking was the six-month rate of cognitive deterioration in both 
arms (85% for WBRT and 52% for SRS, a rather high rate of 
cognitive decline, not previously well-described as a conse-
quence of SRS)8. The rate of surgical bed control was higher in 
patients who received WBRT (78% vs. 57%) as was overall brain 
control (70% vs. 32%). Therefore, SRS is a reasonable option 
for patients after surgery, but patients should be appropriately 
counseled about the high rates of neurocognitive decline after 
SRS (especially because SRS is frequently presented as modal-
ity with negligible cognitive deficits), as well as the enhanced 
risks of local and distant brain failure, without a survival 
advantage over any modality.
Two randomized trials had previously evaluated the role of 
WBRT in addition to SRS for patients with limited brain metas-
tases. The benefit of WBRT in reducing local relapse (27–33% 
without WBRT vs. 11–19% with WBRT) as well as distant brain 
failure (48–64% without WBRT vs. 27–42% with WBRT) was 
observed in both7,9,10. The N0574 study re-examined this ques-
tion by randomizing patients with 1–3 brain metastases to SRS 
with or without WBRT. Consistent with previous studies, this 
trial also demonstrated benefits of WBRT in reducing local fail-
ure (27 vs. 10%) and distant brain failure (30% vs. 8%)11. How-
ever, there was improvement in the rate of cognitive deterioration 
(64% vs. 92% at 3 months) as well as improvement in quality-of-
life in patients treated with SRS alone. Therefore, primary SRS 
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is a reasonable option for patients with limited brain metastases, 
albeit with only modest impact on neurocognition and quality- 
of-life. In practice, we should carefully select the patients 
who receive each of these modalities and identifying patients 
at high risk for neurologic death or intracranial failure may 
help further inform these decisions12.
The aforementioned trials have clarified the role of WBRT in 
patients with poor expected survival, validated the need for 
adjuvant radiotherapy after surgery for brain metastasis, dem-
onstrated the advantages and limitations of SRS after surgery in 
comparison to WBRT, and supported the role of single modality 
focal therapy in patients with limited brain metastases, as long 
as the substantially enhanced risk of intracranial failure is 
acceptable to the patient.
Cognition as a key driver in therapeutic selection
Surveys of brain metastasis patients and oncology nurses reveal 
cognition as an important factor in patient preferences for 
treatment13. Several randomized trials have demonstrated cogni-
tive decline following WBRT, with cognitive function measured 
using a validated, multi-dimensional battery of tests assessing 
episodic memory (HVLT-R), executive function (TMT Part B, 
COWA), processing speed (TMT Part A), and fine motor control 
(Grooved Pegboard)8,10,11. These studies have observed an improve-
ment in the rate of 3-standard deviation decline of cognitive 
testing from baseline to 3-6 months post-treatment from 35–52% 
in WBRT vs. 6–24% after SRS8,11. Interestingly, a significant 
proportion of the cognitive difference between WBRT and SRS 
seems to selectively involve decline in HVLT-R, implying a 
differential sensitivity of episodic memory to WBRT. 
However, demonstration of these cognitive effects has impor-
tant limitations. Since most studies use a time-to-event analysis, 
these trials are limited in their capacity to assess for later 
recovery, following initial decline in cognitive function. How-
ever, since many brain metastasis patients on these trials did 
not live beyond six months, the relevance of such longer-term 
follow-up can be questioned. In addition, while trials have 
demonstrated cognitive and quality-of-life effects following 
WBRT, one study observed decline in episodic memory in addi-
tion to self-reported cognitive complaints; however, minimal 
correlation was seen between decline in tested versus patient-
reported cognitive function14. Such discordance between objec-
tively measured and patient-reported cognitive function has been 
seen in other cognitive disorders such as Alzheimer’s dementia, 
and highlights the need to objectively measure cognition with 
performance-based neuropsychological tests along with patient-
reported outcomes15. Alternatively, it could also provide the 
almost heretical conclusion that patients care less about cogni-
tive test scores and focus more on daily life activity issues that 
these tests do not measure, a very sobering thought!
In a small minority of patients (less than 5%), WBRT can be 
associated with debilitating dementia, which represents the 
more severe end of the spectrum of cognitive decline reported 
in clinical trials16. This severe form of radiation-induced toxic-
ity can manifest as progressive dementia, gait ataxia and urinary 
incontinence – especially in patients treated with hypofractionated 
schedules (>3.5 Gy/fraction)16.
Over the past decade, there have been significant advances in 
the development and testing of pharmacologic and technologic 
approaches for reducing cognitive decline following WBRT. 
Memantine is a non-competitive, low-affinity, open-channel 
antagonist of the N-methyl-D-aspartate (NMDA) receptor that 
blocks pathologically excessive stimulation of NMDA recep-
tors. In pre-clinical models, memantine has been shown to be 
neuro-protective and in two placebo-controlled trials it proved 
to be an effective treatment for vascular dementia17–20. RTOG 
0614 randomized 554 patients with brain metastases receiving 
WBRT to either memantine or placebo21. Although this study 
did not meet its pre-defined endpoint, multiple other endpoints 
were either clinically or statistically significant. For example, 
patients who were randomized to the memantine arm experi-
enced a longer time to cognitive decline as well as a reduced 
risk for cognitive failure following treatment (54% vs. 65%, 
P = 0.01). Furthermore, memantine was neuroprotective in 
multiple cognitive domains including executive function, 
processing speed, and delayed recognition.
Recently, conformal avoidance of the neural stem-cell bearing 
subgranular zone of the hippocampal dentate gyrus using inten-
sity-modulated radiotherapy (IMRT) during WBRT has shown 
significant promise in preventing cognitive toxicity from WBRT. 
The production of new neurons from mitotically active neural 
stem cells found in the subgranular zone of the hippocampal 
dentate gyrus is key to the creation of new memories22. The 
results of preclinical studies show that damage to these neural 
stem cells from even low doses of radiation underpin radio-
therapy-induced cognitive toxicity. Additional clinical stud-
ies have established a dose-response relationship between the 
dose received by the hippocampus and risk of post-radiotherapy 
decline in episodic memory23. Modern hippocampal avoidance 
(HA-WBRT) IMRT techniques have been developed to confor-
mally avoid the hippocampal dentate gyrus while still covering the 
at-risk brain parenchyma14. RTOG 0933, a single-arm phase II trial, 
demonstrated that HA-WBRT was associated with highly prom-
ising preservation of memory and quality-of-life, as compared to 
pre-specified historical controls. Specifically, the primary endpoint 
on this trial, the mean relative decline in HVLT-R delayed recall 
score from baseline to four months was only 7%, significantly 
better in comparison to the 30% decline in the historical control 
(P <0.001). To validate these findings, NRG CC001 (Clinical-
Trials.gov identifier NCT02360215), a phase III, 518-patient 
trial of WBRT with memantine (M) with or without hippoc-
ampal avoidance for patients with brain metastases with the 
primary outcome of time to neurocognitive failure (NCF) was 
completed and presented at the ASTRO Annual Meeting in 
2018. Time to NCF failure was significantly longer in favor of 
HA-WBRT+M. The NCF failure rates following WBRT+M 
vs. HA-WBRT+M were 63.0% vs. 53.7% at four months, and 
69.1% vs. 58.0% at six months (P = 0.012).
NRG CC003 (ClinicalTrials.gov identifier NCT02635009) 
is an ongoing randomized phase II/III trial of prophylactic 
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cranial irradiation with or without hippocampal avoidance for 
small cell lung cancer with the primary outcomes of intracranial 
relapse rate and six-month deterioration in episodic memory; 
the randomized phase II component has completed accrual.
Prior studies comparing cognitive outcomes following SRS 
and WBRT have not included these neuroprotective strate-
gies that may reduce cognitive decline following WBRT. Thus, 
the optimal selection of SRS versus WBRT in the modern era 
of brain metastasis management remains an area of important 
investigation.
The advent of systemic therapies
Traditional cytotoxic chemotherapy had a limited role in the man-
agement of brain metastases due to the presence of the BBB and 
such therapies were associated with low response rates24,25. With 
the advent of targeted therapies and immunotherapy, the role of 
medical therapy is experiencing a resurgence. Targeted thera-
pies have mostly been evaluated in subsets of patients with lung 
cancer, breast cancer, and melanoma. The use of first genera-
tion tyrosine kinase inhibitors (TKIs) that act on EGFR-mutant 
NSCLC brain metastases, such as erlotinib and gefitinib, 
are associated with response rates of 50–80%, and overall 
survival of 12–24 months26–28. Trials with third generation 
TKIs such as osimertinib are associated with response rates of 
55–70% with more durable responses29,30. In the AURA -3 study, 
osimertinib yielded response rates of 70%30. Newer agents that 
target EGFR include AZD-375931,32 and avitinib (targets the 
EGFR T790M resistant mutation)33. In NSCLC brain metastases 
with ALK translocations, the first generation inhibitor crizotinib 
resulted in response rates of 18%34. Newer generation drugs such 
as alectinib35, ceritinib36, and brigatinib37,38 (a combined ALK 
and EGFR inhibitor) with better ability to cross the BBB39, have 
resulted in responses rates of 45–78%.
In breast cancer patients with brain metastases, most targeted 
agents have been evaluated in the HER2-positive setting40. Lapat-
inib, a small molecule TKI inhibitor of HER2, has limited activity 
as a single agent, and has been combined with capecitabine41–43. 
In phase II studies, the lapatinib-capecitabine combination results 
in response rates of 66% in radiotherapy-naive patients and 20% 
in radiation refractory patients41–43. Neratinib has demonstrated 
limited efficacy with responses rates of 8% in HER2-positive 
brain metastases44; however, response rates improve to 49% 
with capecitabine45. Other drugs being examined in this patient 
population include tucatinib and tesevatinib46,47.
Of patients with brain metastases from melanoma, 40–50% 
harbor BRAF mutations, and the use of the BRAF inhibitor 
vemurafenib is associated with 18–20% response rates and 
dabrafenib yields 30–40% response rates48,49. Similar to breast 
cancer patients, higher response rates are seen in patients that are 
radiation naive. The dabrafenib/trematinib combination is associ-
ated with response rates of 55%50. The duration of response with 
dabrafenib and trematinib is approximately six months.
Immunotherapies represent an exciting area of research in 
brain metastases. Drugs that target immune surface proteins 
CTLA4 (ipilimumab) and programmed cell death protein 1 
(PD1) (pembrolizumab and nivolumab) have been devel-
oped and evaluated in patients with lung cancer and melanoma 
brain metastases51. A phase II trial of ipilimumab demonstrated 
disease control rates of 25% in those who were not on steroids and 
10% in patients on steroids52. Phase II trials of pembrolizumab 
showed response rates of 22% in melanoma and 33% in NSCLC53. 
The combination of ipilimumab and nivolumab is associated 
with response rates of 45–57% (in some studies, stable disease 
is included in this measure) in patients with melanoma brain 
metastases54–56. Most of the initial trials evaluated these ICIs or 
receptor tyrosine kinase inhibitors (RTKIs) alone in brain metas-
tases. A number of retrospective studies have shown that these 
agents can safely be used with SRS and have shown improved 
clinical benefit compared to those treated with SRS alone, or 
ICIs/RTKIs alone57. A number of ongoing trials are therefore 
evaluating these agents in combination with WBRT or SRS.
With increasing CNS penetration and intracranial efficacy with 
systemic therapies, a current dilemma in clinical practice is 
the use of upfront SRS at time of brain metastasis diagnosis or 
delayed SRS in patients who fail systemic therapies. Retrospec-
tive data using a strategy of systemic therapy with delayed SRS 
are mixed, with some series demonstrating no difference in 
survival58,59, while others show a detriment to patient outcome 
with upfront systemic therapy alone60. Given the limited data in 
this setting, a randomized study is clearly needed to determine the 
optimal sequencing of available therapies.
Novel molecular insights set the stage for the future
Recent advances in genomic technologies and analytic tools 
have enhanced our understanding of the genetics of brain metas-
tases. Unanswered questions have included whether brain 
metastases are genetically heterogeneous compared to their 
primary tumors, and whether differential clinical responses can be 
explained by such genetic heterogeneity.
A massively parallel sequencing study of one matched brain 
metastasis and a primary breast cancer showed two de novo 
mutations and a deletion in the metastasis and not in the primary 
tumor61. In a comprehensive genomic study of 104 matched brain 
metastases and primary tumors across multiple histologies and a 
variety of treatment regimens, investigators mapped out the 
phylogenetic relationship between brain metastases and primary 
tumors62. An evolutionary pattern of ‘branched’ or divergent 
evolution was ubiquitously observed, meaning the primary tumor 
and brain metastasis shared a common ancestor, yet there was 
significant divergent evolution in each site. As a result of this 
branched evolution pattern, in more than 50% of cases, clini-
cally actionable alterations were present in the brain metastasis, 
and not detected in the primary tumor. This implies that genomic 
characterization of the primary tumor alone to identify thera-
peutic targets may miss potentially clinically significant 
alterations in the brain metastasis. Notably, when multiple regional 
and anatomically distinct brain metastases were analyzed, the 
majority of clinically actionable alterations were shared among 
the intracranial sites, suggesting genomic homogeneity within 
the brain itself. Furthermore, extracranial metastases (as opposed 
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to the primary tumor) displayed divergent evolution and were 
not a genetic surrogate for clinically actionable alterations in the 
brain metastases. These data suggest that genetic heterogene-
ity, at least in part, contributes to divergent therapeutic responses 
within the same patient. This study also demonstrated that 
alterations in the CDK, PI3K/AKT and HER2/EGFR pathways 
were common in brain metastases, suggesting that targeting 
these pathways should be considered. Other investigations have 
confirmed an enrichment of the PI3K/PTEN pathway in brain 
metastases when compared to extracranial sites in melanoma63, 
squamous cell lung cancers64 and breast cancer65. FGFR ampli-
fications are also more enriched in brain metastases from 
lung adenocarcinomas compared to primary tumors, and also 
represent a potential therapeutic target for brain metastases 
patients66. 
Clinical trials should be conducted to answer the question of 
whether targeting the alterations specific to the brain metastasis 
will lead to improved clinical outcomes. Large-scale molecular 
studies of brain metastases across multiple histologic tumor 
types are needed to identify additional therapeutic targets. 
Nevertheless, molecular analysis of brain metastasis tissue, if 
available as part of clinical care, should be considered to identify 
potential targeted therapies.
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